X
    X
    X
    X

    Series A Financing for Mnemosyne Pharmaceuticals

    In 2012, Providence-based Mnemosyne Pharmaceuticals, Inc. announced that it will raise $5,384,496 in its round of equity funding.  We represented, the company in the issuance of series A convertible preferred stock to the investors pursuant to Regulation D of the Securities Act.  The round was led by Access BridgeGap Ventures and included returning investor Slater Technology Fund.

    Disclaimer

    Please understand that your communications with Locke Lord LLP through this website do not constitute or create an attorney-client relationship with Locke Lord LLP. Any information you send to Locke Lord LLP through this website is on a non-confidential and non-privileged basis. Therefore, do not send or include any information in your email that you consider to be confidential or privileged.